How many years should you take Palbociclib at most?

For patients with HR-positive, HER2-negative advanced or metastatic breast cancer, oral palbociclib combination therapy is a valuable emerging option. The safety and efficacy of palbociclib have been demonstrated in the Phase II PALOMA-1 and Phase III PALOMA-2 and PALOMA-3 clinical studies, with the combination of letrozole or fulvestrant significantly improving median progression-free survival (PFS) compared with letrozole alone or placebo plus letrozole or placebo plus fulvestrant.

Although treatment with palbociclib plus letrozole or fulvestrant was associated with longer median overall survival (OS) compared with letrozole alone or placebo plus fulvestrant, respectively, in PALOMA-1 or PALOMA-3, the results were not statistically significant. Several treatments for patients with breast cancer are associated with long-term or potential adverse events. The 5-year long-term analysis showed that palbociclib plus endocrine therapy had a consistent and stable safety profile with no cumulative or delayed toxicities. These results further support clinical practice.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.